A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Protocol No
AZ-D822GC00001-TRAVERSE
Phase
II
Summary

This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).

Description
This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL